Do you suffer from migraines?
If you have between 2-8 migraines per month, you may qualify to participate in a study to help us learn about a new investigational medication being tested for the acute treatment of migraines.
Acute Treatment of Migraine Study
Biohaven Pharmaceuticals is studying a new drug, called zavegepant for the acute treatment of migraines. If you are at least 18 years of age and have had migraine for at least 1 year, you may qualify.
Health insurance is not required to take part in this study and compensation for participation may also be provided. Learn more >>
Who is this study for?
You may qualify for this study if you meet the following criteria:
You are 18 years of age or older.
You must have at least 1-year history of migraine (with or without aura) including the following:
Age of onset of migraines prior to 50 years of age
Migraine attacks, on average, lasting 4 - 72 hours if untreated.
2 - 8 migraine attacks of moderate to severe intensity per month within the last 3 months prior to the screening visit (first visit at the study site).
Ability to distinguish migraine attacks from tension/cluster headaches.
The migraine study clinicians will further assess your medical and migraine history to determine your eligibility.
You may receive
If you qualify for the study you may receive:
Study-related evaluations of your migraine-related symptoms and overall health.*
You may receive compensation for your participation.
*You do not need insurance to participate.
What is a clinical trial?
Before a medication can be approved for treatment, the FDA requires that it be tested in a clinical study to evaluate the safety and efficacy of the drug.
Clinical trials take place in medical centers around the world, and involve volunteers helping doctors look at new ways to treat conditions.
Clinical trials represent the latest research about your condition, and can offer new treatment options.
Click the button below to see if you qualify for this study: